Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Barclays analyst Peter Lawson maintained a Hold rating on Exelixis (EXEL – Research Report) today and set a price target of $25.00. The company’s shares closed yesterday at $36.43. Lawson ...

Riverwater Partners Sustainable Value Strategy highlighted stocks like Exelixis, Inc. (NASDAQ:EXEL), in the fourth quarter 2024 investor letter. Exelixis, Inc. (NASDAQ:EXEL) is an oncology company ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Techne (TECH). But which of these two companies is the best option for those looking ...

EXEL is not in the business of me-too programs ... We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything. This isn’t a maybe ...

As the logistics industry prepares for a more positive 2025, the potential for automation — utilizing machine learning and AI — to impact operations has never been more significant. From optimizing ...

Supporting Saudi Arabia’s vision to become a global gaming hub Riyadh, Saudi Arabia – Exel by Merak, the new gaming accelerator funded by Merak Capital’s $80 million gaming fund, is now accepting ...

Below is Validea's guru fundamental report for EXELIXIS INC (EXEL). Of the 22 guru strategies we follow, EXEL rates highest using our Multi-Factor Investor model based on the published strategy of ...

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx ...